Manon Jammes

Ms. Manon Jammes

Université de Caen Normandie, Caen, Normandie, France
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
RCRomain Contentin
Romain Contentin
MJManon Jammes
Manon Jammes
BBBastien Bourdon
Bastien Bourdon
FCFrédéric Cassé
Frédéric Cassé
Arnaud BianchiArnaud Bianchi
Arnaud Bianchi
PGPhilippe GALERA
Philippe GALERA
Equine osteoarthritis (OA) leads to cartilage degradation with impaired animal well-being, premature cessation of sport activity, and financial losses. Mesenchymal stem cell (MSC)-based therapies are promising for cartilage repair, but face limitations inherent to the cell itself. Soluble mediators and extracellular vesicles (EVs) secreted by MSCs are the alternatives to overcome those limitations while preserving MSC restorative properties. The effect of equine bone marrow MSC secretome on equine articular chondrocytes (eACs) was analyzed with indirect co-culture and/or MSC-conditioned media (CM). The expression of healthy cartilage/OA and proliferation markers was evaluated in eACs (monolayers or organoids). In vitro repair experiments with MSC-CM were made to evaluate the proliferation and migration of eACs. The presence of nanosized EVs in MSC-CM was appraised with nanoparticle tracking assay and transmission electron microscopy. Our results demonstrated that the MSC secretome influences eAC phenotype by increasing cartilage functionality markers and cell migration in a greater way than MSCs, which could delay OA final outcomes. This study makes acellular therapy an appealing strategy to improve equine OA treatments. However, the MSC secretome contains a wide variety of soluble mediators and small EVs, such as exosomes, and further investigation must be performed to understand the mechanisms occurring behind these promising effects.

20 December 2024 in Progress in Retinal and Eye Research
Verified
Journal Article
Open access
MJManon Jammes
Manon Jammes
ATAbbas Tabasi
Abbas Tabasi
TBTrung Bach
Trung Bach
TRThomas Ritter
Thomas Ritter
Affecting a large proportion of the population worldwide, corneal disorders constitute a concerning health hazard associated to compromised eyesight or blindness for most severe cases. In the last decades, mesenchymal stem/stromal cells (MSCs) demonstrated promising abilities in improving symptoms associated to corneal diseases or alleviating these affections, especially through their anti-inflammatory, immunomodulatory and pro-regenerative properties. More recently, MSC therapeutic potential was shown to be mediated by the molecules they release, and particularly by their extracellular vesicles (EVs; MSC-EVs). Consequently, using MSC-EVs emerged as a pioneering strategy to mitigate the risks related to cell therapy while providing MSC therapeutic benefits. Despite the promises given by MSC- and MSC-EV-based approaches, many improvements are considered to optimize the therapeutic significance of these therapies. This review aspires to provide a comprehensive and detailed overview of current knowledge on corneal therapies involving MSCs and MSC-EVs, the strategies currently under evaluation, and the gaps remaining to be addressed for clinical implementation. From encapsulating MSCs or their EVs into biomaterials to enhance the ocular retention time to loading MSC-EVs with therapeutic drugs, a wide range of ground-breaking strategies are currently contemplated to lead to the safest and most effective treatments. Promising research initiatives also include diverse gene therapies and the targeting of specific cell types through the modification of the EV surface, paving the way for future therapeutic innovations. As one of the most important challenges, MSC-EV large-scale production strategies are extensively investigated and offer a wide array of possibilities to meet the needs of clinical applications.

Verified
Journal Article
Open access
PDF file
MJManon Jammes
Manon Jammes
FCFrédéric Cassé
Frédéric Cassé
ÉVÉmilie Velot
Émilie Velot
Arnaud BianchiArnaud Bianchi
Arnaud Bianchi
FAFabrice AUDIGIE
Fabrice AUDIGIE
PGPhilippe GALERA
Philippe GALERA
Osteoarthritis (OA) is a widespread osteoarticular pathology characterized by progressive hyaline cartilage degradation, exposing horses to impaired well-being, premature career termination, alongside substantial financial losses for horse owners. Among the new therapeutic strategies for OA, using mesenchymal stromal cell (MSC)-derived exosomes (MSC-exos) appears to be a promising option for conveying MSC therapeutic potential, yet avoiding the limitations inherent to cell therapy. Here, we first purified and characterized exosomes from MSCs by membrane affinity capture (MAC) and size-exclusion chromatography (SEC). We showed that intact MSC-exos are indeed internalized by equine articular chondrocytes (eACs), and then evaluated their functionality on cartilaginous organoids. Compared to SEC, mRNA and protein expression profiles revealed that MAC-exos induced a greater improvement of eAC-neosynthesized hyaline-like matrix by modulating collagen levels, increasing PCNA, and decreasing Htra1 synthesis. However, because the MAC elution buffer induced unexpected effects on eACs, an ultrafiltration step was included to the isolation protocol. Finally, exosomes from MSCs primed with equine pro-inflammatory cytokines (IL-1β, TNF-α, or IFN-γ) further improved the eAC hyaline-like phenotype, particularly IL-1β and TNF-α. Altogether, these findings indicate the importance of the exosome purification method and further demonstrate the potential of pro-inflammatory priming in the enhancement of the therapeutic value of MSC-exos for equine OA treatment.

16 March 2022 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
CVClement Veys
Clement Veys
MJManon Jammes
Manon Jammes
FRFrancoise Redini
Francoise Redini
LPLaurent Poulain
Laurent Poulain
CDChristophe Denoyelle
Christophe Denoyelle
PGPhilippe GALERA
Philippe GALERA
Osteosarcomas are the most common type of malignant bone tumor. These tumors are characterized by the synthesis of an osteoid matrix. Current treatments are based on surgery and combination chemotherapy. However, for metastatic or recurrent tumors, chemotherapy is generally ineffective, and osteosarcomas are sometimes unresectable. Thus, the use of microRNAs (miRNAs) may represent an attractive alternative for the development of new therapies. Using high-throughput functional screening based on impedancemetry, we previously selected five miRNAs with potential chemosensitizing or antiproliferative effects on chondrosarcoma cells. We validated the tumor-suppressive activity of miR-491-5p and miR-342-5p in three chondrosarcoma cell lines. Here, we carried out individual functional validation of these five miRNAs in three osteosarcoma cell lines used as controls to evaluate their specificity of action on another type of bone sarcoma. The cytotoxic effects of miR-491-5p and miR-342-5p were also confirmed in osteosarcoma cells. Both miRNAs induced apoptosis. They increased Bcl-2 homologous antagonist killer (Bak) protein expression and directly targeted Bcl-2 lymphoma-extra large (Bcl-xL). MiR-342-5p also decreased B-cell lymphoma-2 (Bcl-2) protein expression, and miR-491-5p decreased that of Epidermal Growth Factor Receptor (EGFR). MiR-342-5p and miR-491-5p show tumor-suppressive activity in osteosarcomas. This study also confirms the potential of Bcl-xL as a therapeutic target in osteosarcomas.

7 April 2026
Verified
Thesis
Closed access
MJManon Jammes
Manon Jammes
Le cartilage hyalin est un tissu conjonctif recouvrant les extrémités des os et assurant le bon fonctionnement des articulations synoviales. Au cours du vieillissement ou suite à des traumatismes physiques, le cartilage peut subir des lésions et se dégrader progressivement, menant au développement de l’arthrose dont les symptômes se manifestent sous la forme de douleurs, de gonflements et de l’inflammation de l’articulation. Du fait de l’exposition des chevaux à des compétitions sportives intenses et fréquentes, l’arthrose est fortement prévalente dans la filière équine, entraînant l’altération du bien-être animal ainsi que d’importantes pertes économiques. Actuellement, seuls des traitements palliatifs sont disponibles, cependant, l’utilisation du sécrétome de cellules souches mésenchymateuses de moelle osseuse (CSM-MO) émerge comme une solution thérapeutique innovante tout en s’affranchissant de certaines contraintes liées aux thérapies cellulaires. Définit comme l’ensemble des particules et éléments bioactifs sécrétés par les cellules, le sécrétome contient également des nanovésicules extracellulaires (nVE) dont une catégorie, les exosomes, présente une composition et des capacités de vectorisation séduisantes pour la régénération du cartilage. Dans ce contexte, les objectifs de ces travaux de thèse étaient de produire, caractériser et évaluer le potentiel du sécrétome des CSM-MO équines, ainsi que de leurs nVE, pour la régénération des lésions chondrales chez le cheval. Premièrement, nous avons collecté le sécrétome de CSM-MO équines en culture monocouche via la production de milieux conditionnés (MC). Ces MC ont permis de favoriser in vitro la migration des chondrocytes et d’augmenter la synthèse des collagènes de types I, II et IIB dans des organoïdes cartilagineux in vitro. Par la suite, trois cytokines pro-inflammatoires équines (IL-1β, TNF-α et IFN-γ) ont été utilisées pour stimuler les propriétés immunomodulatrices des CSM. Le traitement des chondrocytes par du MC obtenu après le priming des CSM par de l’IL-1β et du TNF-α a permis d’induire l’accumulation des collagènes I et IIB dans la matrice extracellulaire, tandis que l’IFN-γ a entraîné une diminution de leur expression. À l’inverse, le niveau des ARNm de certaines protéases matricielles s’est vu diminué lorsque le MC était obtenu après priming par l’IFN-γ et augmenté lors du priming par les deux autres cytokines. L’utilisation thérapeutique des exosomes étant plus avantageuse que celle du sécrétome complet, nous avons ensuite purifié les exosomes de CSM-MO par capture par membrane d’affinité (MAC) et chromatographie par exclusion de taille (SEC). La MAC a permis d’obtenir un rendement plus important que la SEC, malgré une plus faible pureté des exosomes. De plus, les exosomes isolés par MAC ont démontré un meilleur potentiel pour l’amélioration du phénotype chondrocytaire de type hyalin. La modulation de ce potentiel via le priming des CSM a révélé des effets spécifiques à chaque type d’exosomes. Ces travaux initient le développement de stratégies innovantes basées sur le sécrétome et les exosomes de CSM-MO pour la régénération du cartilage et le traitement de l’arthrose équine. Au vu des similitudes partagées par les articulations humaines et équines, ces études initiées chez le cheval ouvrent de vastes perspectives thérapeutiques en médecine clinique selon les préceptes du concept « One Health ».